Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CCND2 | P30279 | 1/20 | 0.31 |
| ▸ | CCND3 | P30281 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663450 | 0.82 | PIK3CD (0.32) | PIK3CDPIK3R1ADORA2BGRM4PIK3CG | |
| SCHEMBL29663177 | 0.82 | ADORA2B (0.33) | PIK3CDPIK3R1ADORA2BPIK3CG | |
| SCHEMBL29663510 | 0.78 | JMJD6 (0.34) | PIK3CDPIK3R1ADORA2B | |
| SCHEMBL29663583 | 0.74 | PIK3CD (0.32) | PIK3CDPIK3R1 | |
| SCHEMBL29663208 | 0.71 | CREBBP (0.47) | PIK3CDPIK3R1 | |
| SCHEMBL29663550 | 0.70 | KDM5B (0.41) | PIK3CDPIK3CG | |
| SCHEMBL29663430 | 0.69 | KDM5B (0.43) | PIK3CDADORA2BPIK3CG | |
| SCHEMBL29663488 | 0.68 | CDK4 (0.32) | ADORA2BCDK4CCND1CCND2CCND3 | |
| SCHEMBL29663279 | 0.67 | ADORA2B (0.36) | ADORA2B | |
| SCHEMBL23119748 | 0.64 | ADORA2B (0.44) | ADORA2BGRM4CDK4CCND1CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-3999183-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | Ono Pharmaceutical Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | KDM5A, KDM1B, KDM5D | PIK3CD 2208/4885PIK3R1 1113/4885ADORA2B 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.